APO Research
Talk to an analyst

APO RESEARCH · REPORT

Natamycin

Natamycin, also sold as Natacyn, is a type of white powder that fermented by the bacterium Streptomyces natalensis. Natamycin has an ability to inhibit fungal growth but cannot inhibit the growth of bacteria, it is often used in food industry like yogurt, cheese, raw ham, dry sausage as a natural preservative. Natamycin can also be used in medicine to treat diseases caused by fungi.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Natamycin, also sold as Natacyn, is a type of white powder that fermented by the bacterium Streptomyces natalensis. Natamycin has an ability to inhibit fungal growth but cannot inhibit the growth of bacteria, it is often used in food industry like yogurt, cheese, raw ham, dry sausage as a natural preservative. Natamycin can also be used in medicine to treat diseases caused by fungi.

Selected research

Market Outlook & Growth Opportunities

Global Natamycin Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchNatamycin Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Natamycin Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Natamycin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Natamycin Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Natamycin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Natamycin, also sold as Natacyn, is a type of white powder that fermented by the bacterium Streptomyces natalensis. Natamycin has an ability to inhibit fungal growth but cannot inhibit the growth of bacteria, it is often used in food industry like yogurt, cheese, raw ham, dry sausage as a natural preservative. Natamycin can also be used in medicine to treat diseases caused by fungi.

Global Natamycin key players include Danisco, DSM, VGP, Handary, AMTECH BIOTECH, etc. Global top five players hold a share about 50%.

North America is the largest market, with a share about 35%, followed by Europe and China, having a total share about 35 percent.

Read the full market overview

In terms of product, the segment includes Glucose-based, Lactose-based, Sodium chloride-based. And in terms of application, the application includes Food Industry, Medical, etc.

This report provides an overview of the global Natamycin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Natamycin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Natamycin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Natamycin market size, projected growth trends, production technologies, key applications, and end-use industries.

Natamycin Segment by Company

Danisco

DSM

VGP

Handary

AMTECH BIOTECH

Silver-Elephant

Lanzhou Weiri

Langfang Meihua

Zhengzhou New Frey

Chihon

Jiaozuo Joincare

Beijing Oriental Rada

Pucheng Lifecome

Natamycin Segment by Type

Glucose-based

Lactose-based

Sodium chloride-based

Natamycin Segment by Application

Food

Medical

Others

Natamycin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Natamycin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Natamycin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Natamycin significant trends, drivers, influence factors in global and regions.

6. To analyze Natamycin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Natamycin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Natamycin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Natamycin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Natamycin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Natamycin industry.

Chapter 3: Detailed analysis of Natamycin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Natamycin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Natamycin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Natamycin Industry Trends Table 2. Natamycin Industry Drivers Table 3. Natamycin Industry Opportunities and Challenges Table 4. Natamycin Industry Restraints Table 5. Global Natamycin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Natamycin Revenue Share by Company (2021-2026) Table 7. Global Natamycin Sales Volume by Company (MT) & (2021-2026) Table 8. Global Natamycin Sales Volume Share by Company (2021-2026) Table 9. Global Natamycin Average Price (USD/MT) of Company (2021-2026) Table 10. Global Natamycin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Natamycin Key Company Manufacturing Base & Headquarters Table 12. Global Natamycin Company, Product Type & Application Table 13. Global Natamycin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Natamycin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Glucose-based Table 18. Significant Companies of Lactose-based Table 19. Significant Companies of Sodium chloride-based Table 20. Global Natamycin Sales Volume by Type 2021 VS 2025 VS 2032 (MT) Table 21. Global Natamycin Sales Volume by Type (2021-2026) & (MT) Table 22. Global Natamycin Sales Volume by Type (2027-2032) & (MT) Table 23. Global Natamycin Sales Volume Share by Type (2021-2026) Table 24. Global Natamycin Sales Volume Share by Type (2027-2032) Table 25. Global Natamycin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Natamycin Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Natamycin Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Natamycin Sales Value Share by Type (2021-2026) Table 29. Global Natamycin Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Food Table 31. Significant Companies of Medical Table 32. Significant Companies of Others Table 33. Global Natamycin Sales Volume by Application 2021 VS 2025 VS 2032 (MT) Table 34. Global Natamycin Sales Volume by Application (2021-2026) & (MT) Table 35. Global Natamycin Sales Volume by Application (2027-2032) & (MT) Table 36. Global Natamycin Sales Volume Share by Application (2021-2026) Table 37. Global Natamycin Sales Volume Share by Application (2027-2032) Table 38. Global Natamycin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Natamycin Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Natamycin Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Natamycin Sales Value Share by Application (2021-2026) Table 42. Global Natamycin Sales Value Share by Application (2027-2032) Table 43. Global Natamycin Sales by Region: 2021 VS 2025 VS 2032 (MT) Table 44. Global Natamycin Sales by Region (2021-2026) & (MT) Table 45. Global Natamycin Sales Market Share by Region (2021-2026) Table 46. Global Natamycin Sales by Region (2027-2032) & (MT) Table 47. Global Natamycin Sales Market Share by Region (2027-2032) Table 48. Global Natamycin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Natamycin Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Natamycin Sales Value Share by Region (2021-2026) Table 51. Global Natamycin Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Natamycin Sales Value Share by Region (2027-2032) Table 53. Global Natamycin Market Average Price (USD/MT) by Region (2021-2026) Table 54. Global Natamycin Market Average Price (USD/MT) by Region (2027-2032) Table 55. Global Natamycin Sales by Country: 2021 VS 2025 VS 2032 (MT) Table 56. Global Natamycin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Natamycin Sales by Country (2021-2026) & (MT) Table 58. Global Natamycin Sales Market Share by Country (2021-2026) Table 59. Global Natamycin Sales by Country (2027-2032) & (MT) Table 60. Global Natamycin Sales Market Share by Country (2027-2032) Table 61. Global Natamycin Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Natamycin Sales Value Market Share by Country (2021-2026) Table 63. Global Natamycin Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Natamycin Sales Value Market Share by Country (2027-2032) Table 65. Danisco Company Information Table 66. Danisco Business Overview Table 67. Danisco Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 68. Danisco Natamycin Product Portfolio Table 69. Danisco Recent Development Table 70. DSM Company Information Table 71. DSM Business Overview Table 72. DSM Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 73. DSM Natamycin Product Portfolio Table 74. DSM Recent Development Table 75. VGP Company Information Table 76. VGP Business Overview Table 77. VGP Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 78. VGP Natamycin Product Portfolio Table 79. VGP Recent Development Table 80. Handary Company Information Table 81. Handary Business Overview Table 82. Handary Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 83. Handary Natamycin Product Portfolio Table 84. Handary Recent Development Table 85. AMTECH BIOTECH Company Information Table 86. AMTECH BIOTECH Business Overview Table 87. AMTECH BIOTECH Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 88. AMTECH BIOTECH Natamycin Product Portfolio Table 89. AMTECH BIOTECH Recent Development Table 90. Silver-Elephant Company Information Table 91. Silver-Elephant Business Overview Table 92. Silver-Elephant Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 93. Silver-Elephant Natamycin Product Portfolio Table 94. Silver-Elephant Recent Development Table 95. Lanzhou Weiri Company Information Table 96. Lanzhou Weiri Business Overview Table 97. Lanzhou Weiri Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 98. Lanzhou Weiri Natamycin Product Portfolio Table 99. Lanzhou Weiri Recent Development Table 100. Langfang Meihua Company Information Table 101. Langfang Meihua Business Overview Table 102. Langfang Meihua Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 103. Langfang Meihua Natamycin Product Portfolio Table 104. Langfang Meihua Recent Development Table 105. Zhengzhou New Frey Company Information Table 106. Zhengzhou New Frey Business Overview Table 107. Zhengzhou New Frey Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 108. Zhengzhou New Frey Natamycin Product Portfolio Table 109. Zhengzhou New Frey Recent Development Table 110. Chihon Company Information Table 111. Chihon Business Overview Table 112. Chihon Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 113. Chihon Natamycin Product Portfolio Table 114. Chihon Recent Development Table 115. Jiaozuo Joincare Company Information Table 116. Jiaozuo Joincare Business Overview Table 117. Jiaozuo Joincare Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 118. Jiaozuo Joincare Natamycin Product Portfolio Table 119. Jiaozuo Joincare Recent Development Table 120. Beijing Oriental Rada Company Information Table 121. Beijing Oriental Rada Business Overview Table 122. Beijing Oriental Rada Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 123. Beijing Oriental Rada Natamycin Product Portfolio Table 124. Beijing Oriental Rada Recent Development Table 125. Pucheng Lifecome Company Information Table 126. Pucheng Lifecome Business Overview Table 127. Pucheng Lifecome Natamycin Sales (MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 128. Pucheng Lifecome Natamycin Product Portfolio Table 129. Pucheng Lifecome Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Natamycin Distributors List Table 133. Natamycin Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Natamycin Product Image Figure 2. Global Natamycin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Natamycin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Natamycin Sales (2021-2032) & (MT) Figure 5. Global Natamycin Sales Average Price (USD/MT) & (2021-2032) Figure 6. Global Natamycin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Glucose-based Image Figure 10. Lactose-based Image Figure 11. Sodium chloride-based Image Figure 12. Global Natamycin Sales Volume by Type (2021 VS 2025 VS 2032) & (MT) Figure 13. Global Natamycin Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Natamycin Sales Volume Share by Type (2021-2032) Figure 15. Global Natamycin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Natamycin Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Natamycin Sales Value Share by Type (2021-2032) Figure 18. Food Image Figure 19. Medical Image Figure 20. Others Image Figure 21. Global Natamycin Sales Volume by Application (2021 VS 2025 VS 2032) & (MT) Figure 22. Global Natamycin Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Natamycin Sales Volume Share by Application (2021-2032) Figure 24. Global Natamycin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Natamycin Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Natamycin Sales Value Share by Application (2021-2032) Figure 27. Global Natamycin Sales by Region: 2021 VS 2025 VS 2032 (MT) Figure 28. Global Natamycin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Natamycin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Natamycin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Natamycin Sales Value (2021-2032) & (US$ Million) Figure 32. North America Natamycin Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Natamycin Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Natamycin Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Natamycin Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Natamycin Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Natamycin Sales Value (2021-2032) & (US$ Million) Figure 38. South America Natamycin Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Natamycin Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Natamycin Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Natamycin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Natamycin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Natamycin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Natamycin Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Natamycin Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Glucose-based
  • Lactose-based
  • Sodium chloride-based
Applications
  • Food
  • Medical
  • Others
Companies covered
  • Danisco
  • DSM
  • VGP
  • Handary
  • AMTECH BIOTECH
  • Silver-Elephant
  • Lanzhou Weiri
  • Langfang Meihua
  • Zhengzhou New Frey
  • Chihon
  • Jiaozuo Joincare
  • Beijing Oriental Rada
  • Pucheng Lifecome

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Natamycin Sales Value (2021-2032)
  4. 1.2.2 Global Natamycin Sales Volume (2021-2032)
  5. 1.2.3 Global Natamycin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Natamycin Market Dynamics
  1. 2.1 Natamycin Industry Trends
  2. 2.2 Natamycin Industry Drivers
  3. 2.3 Natamycin Industry Opportunities and Challenges
  4. 2.4 Natamycin Industry Restraints
3 Natamycin Market by Company
  1. 3.1 Global Natamycin Company Revenue Ranking in 2025
  2. 3.2 Global Natamycin Revenue by Company (2021-2026)
  3. 3.3 Global Natamycin Sales Volume by Company (2021-2026)
  4. 3.4 Global Natamycin Average Price by Company (2021-2026)
  5. 3.5 Global Natamycin Company Ranking (2024-2026)
  6. 3.6 Global Natamycin Company Manufacturing Base and Headquarters
  7. 3.7 Global Natamycin Company Product Type and Application
  8. 3.8 Global Natamycin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Natamycin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Natamycin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Natamycin Market by Type
  1. 4.1 Natamycin Type Introduction
  2. 4.1.1 Glucose-based
  3. 4.1.2 Lactose-based
  4. 4.1.3 Sodium chloride-based
  5. 4.2 Global Natamycin Sales Volume by Type
  6. 4.2.1 Global Natamycin Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Natamycin Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Natamycin Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Natamycin Sales Value by Type
  10. 4.3.1 Global Natamycin Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Natamycin Sales Value by Type (2021-2032)
  12. 4.3.3 Global Natamycin Sales Value Share by Type (2021-2032)
5 Natamycin Market by Application
  1. 5.1 Natamycin Application Introduction
  2. 5.1.1 Food
  3. 5.1.2 Medical
  4. 5.1.3 Others
  5. 5.2 Global Natamycin Sales Volume by Application
  6. 5.2.1 Global Natamycin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Natamycin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Natamycin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Natamycin Sales Value by Application
  10. 5.3.1 Global Natamycin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Natamycin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Natamycin Sales Value Share by Application (2021-2032)
6 Natamycin Regional Sales and Value Analysis
  1. 6.1 Global Natamycin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Natamycin Sales by Region (2021-2032)
  3. 6.2.1 Global Natamycin Sales by Region: 2021-2026
  4. 6.2.2 Global Natamycin Sales by Region (2027-2032)
  5. 6.3 Global Natamycin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Natamycin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Natamycin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Natamycin Sales Value by Region (2027-2032)
  9. 6.5 Global Natamycin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Natamycin Sales Value (2021-2032)
  12. 6.6.2 North America Natamycin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Natamycin Sales Value (2021-2032)
  15. 6.7.2 Europe Natamycin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Natamycin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Natamycin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Natamycin Sales Value (2021-2032)
  21. 6.9.2 South America Natamycin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Natamycin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Natamycin Sales Value Share by Country, 2025 VS 2032
7 Natamycin Country-level Sales and Value Analysis
  1. 7.1 Global Natamycin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Natamycin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Natamycin Sales by Country (2021-2032)
  4. 7.3.1 Global Natamycin Sales by Country (2021-2026)
  5. 7.3.2 Global Natamycin Sales by Country (2027-2032)
  6. 7.4 Global Natamycin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Natamycin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Natamycin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Natamycin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Natamycin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Natamycin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Natamycin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Natamycin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Natamycin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Natamycin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Natamycin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Natamycin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Natamycin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Natamycin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Natamycin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Natamycin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Natamycin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Natamycin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Natamycin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Natamycin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Natamycin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Natamycin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Natamycin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Natamycin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Natamycin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Natamycin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Natamycin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Natamycin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Natamycin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Natamycin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Natamycin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Natamycin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Natamycin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Natamycin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Natamycin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Natamycin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Natamycin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Natamycin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Natamycin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Natamycin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Natamycin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Natamycin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Natamycin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Natamycin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Natamycin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Natamycin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Natamycin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Natamycin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Natamycin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Natamycin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Natamycin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Natamycin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Natamycin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Natamycin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Natamycin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Natamycin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Natamycin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Natamycin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Natamycin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Natamycin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Natamycin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Natamycin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Natamycin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Natamycin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Natamycin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Natamycin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Natamycin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Natamycin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Natamycin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Natamycin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Natamycin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Natamycin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Natamycin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Natamycin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Natamycin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Natamycin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Natamycin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Natamycin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Natamycin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Natamycin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Natamycin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Natamycin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Natamycin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Natamycin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Natamycin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Natamycin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Natamycin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Danisco
  2. 8.1.1 Danisco Company Information
  3. 8.1.2 Danisco Business Overview
  4. 8.1.3 Danisco Natamycin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Danisco Natamycin Product Portfolio
  6. 8.1.5 Danisco Recent Developments
  7. 8.2 DSM
  8. 8.2.1 DSM Company Information
  9. 8.2.2 DSM Business Overview
  10. 8.2.3 DSM Natamycin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 DSM Natamycin Product Portfolio
  12. 8.2.5 DSM Recent Developments
  13. 8.3 VGP
  14. 8.3.1 VGP Company Information
  15. 8.3.2 VGP Business Overview
  16. 8.3.3 VGP Natamycin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 VGP Natamycin Product Portfolio
  18. 8.3.5 VGP Recent Developments
  19. 8.4 Handary
  20. 8.4.1 Handary Company Information
  21. 8.4.2 Handary Business Overview
  22. 8.4.3 Handary Natamycin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Handary Natamycin Product Portfolio
  24. 8.4.5 Handary Recent Developments
  25. 8.5 AMTECH BIOTECH
  26. 8.5.1 AMTECH BIOTECH Company Information
  27. 8.5.2 AMTECH BIOTECH Business Overview
  28. 8.5.3 AMTECH BIOTECH Natamycin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AMTECH BIOTECH Natamycin Product Portfolio
  30. 8.5.5 AMTECH BIOTECH Recent Developments
  31. 8.6 Silver-Elephant
  32. 8.6.1 Silver-Elephant Company Information
  33. 8.6.2 Silver-Elephant Business Overview
  34. 8.6.3 Silver-Elephant Natamycin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Silver-Elephant Natamycin Product Portfolio
  36. 8.6.5 Silver-Elephant Recent Developments
  37. 8.7 Lanzhou Weiri
  38. 8.7.1 Lanzhou Weiri Company Information
  39. 8.7.2 Lanzhou Weiri Business Overview
  40. 8.7.3 Lanzhou Weiri Natamycin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lanzhou Weiri Natamycin Product Portfolio
  42. 8.7.5 Lanzhou Weiri Recent Developments
  43. 8.8 Langfang Meihua
  44. 8.8.1 Langfang Meihua Company Information
  45. 8.8.2 Langfang Meihua Business Overview
  46. 8.8.3 Langfang Meihua Natamycin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Langfang Meihua Natamycin Product Portfolio
  48. 8.8.5 Langfang Meihua Recent Developments
  49. 8.9 Zhengzhou New Frey
  50. 8.9.1 Zhengzhou New Frey Company Information
  51. 8.9.2 Zhengzhou New Frey Business Overview
  52. 8.9.3 Zhengzhou New Frey Natamycin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zhengzhou New Frey Natamycin Product Portfolio
  54. 8.9.5 Zhengzhou New Frey Recent Developments
  55. 8.10 Chihon
  56. 8.10.1 Chihon Company Information
  57. 8.10.2 Chihon Business Overview
  58. 8.10.3 Chihon Natamycin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chihon Natamycin Product Portfolio
  60. 8.10.5 Chihon Recent Developments
  61. 8.11 Jiaozuo Joincare
  62. 8.11.1 Jiaozuo Joincare Company Information
  63. 8.11.2 Jiaozuo Joincare Business Overview
  64. 8.11.3 Jiaozuo Joincare Natamycin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Jiaozuo Joincare Natamycin Product Portfolio
  66. 8.11.5 Jiaozuo Joincare Recent Developments
  67. 8.12 Beijing Oriental Rada
  68. 8.12.1 Beijing Oriental Rada Company Information
  69. 8.12.2 Beijing Oriental Rada Business Overview
  70. 8.12.3 Beijing Oriental Rada Natamycin Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Beijing Oriental Rada Natamycin Product Portfolio
  72. 8.12.5 Beijing Oriental Rada Recent Developments
  73. 8.13 Pucheng Lifecome
  74. 8.13.1 Pucheng Lifecome Company Information
  75. 8.13.2 Pucheng Lifecome Business Overview
  76. 8.13.3 Pucheng Lifecome Natamycin Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pucheng Lifecome Natamycin Product Portfolio
  78. 8.13.5 Pucheng Lifecome Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Natamycin Value Chain Analysis
  2. 9.1.1 Natamycin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Natamycin Sales Mode & Process
  6. 9.2 Natamycin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Natamycin Distributors
  9. 9.2.3 Natamycin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst